About
Connect to Cure™
Synaffix is a biotech company with a clinical-stage platform technology that enables best-in-class antibody-drug conjugates (ADCs), bispecific antibodies and other targeted therapeutics under a technology out-licensing business model. Synaffix was fully acquired by Lonza in June 2023.
Aimed at enabling innovative medicines for patients in areas of high unmet medical need, Synaffix has forged a growing number of collaborations with top tier biotech and pharma companies by enabling best-in-class therapeutic candidates for their pipelines.
Company Timeline
Deal with Macrogenics (NASDAQ:MGNX)
Synaffix signs out-licensing deal with Macrogenics worth up to $586m
Deal with Genmab (NASDAQ:GMAB)
Synaffix signs exclusive out-licensing deal with Genmab worth up to $415m
Deal with Mersana (NASDAQ:MRSN) Expanded
Synaffix expands the 2019 deal with Mersana to over $1 billion.
Deal with Kyowa Kirin (TYO:4151)
Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
Deal with ProfoundBio
Synaffix signs out-licensing deal with ProfoundBio worth up to $246m
Deal with Innovent (1801:HK)
Synaffix signs out-licensing deal with Innovent, providing access to GlycoConnect™, HydraSpace™ and toxSYN™ platforms for ADC development and commercialization
Winner "Best ADC Platform Technology" Award
Synaffix awarded “Best ADC Platform Technology” at World ADC Awards ceremony
Deal with Miracogen
Synaffix signs out-licensing deal with Miracogen worth up to $125m
Deal with Mersana (NASDAQ:MRSN)
Synaffix signs out-licensing deal with Mersana worth up to $295m
toxSYN™ Linker-Payloads Launched
Synaffix launches toxSYN™ linker-payloads as extension of its existing platform, enabling any company with an antibody to develop proprietary, best-in-class ADCs
Deal with ADC Therapeutics (NYSE:ADCT)
Synaffix signs initial out-licensing deal with ADC Therapeutics, providing access to GlycoConnect™ and HydraSpace™ for ADC development and commercialization
High Potency Lab Opens
High potency lab comes online, facilitating safe handling of highly-potent ADCs and ADC payloads
SAB Established
Leading industry experts appointed to Scientific Advisory Board (SAB)
Series A Financing
Series A financing, backed by top-tier investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and M Ventures
